Publications

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SNing, Reiter A, Siebert R, Melnick A et al..  2011.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.. PLoS One. 6(4):e18436.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.

Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A.  2010.  DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.. Blood. 116(20):e81-9.

Navigante AH, Castro MA, Cerchietti LC.  2010.  Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated.. J Pain Symptom Manage. 39(5):820-30.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.

Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH et al..  2010.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.. Cancer Cell. 17(4):400-11.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.

Cerchietti LC, Yang SNing, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.  2009.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.. Blood. 113(15):3397-405.

Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.

Bonomi M, Blanco-Savorio A, Cerchietti L, Navigante A, Castro M, Roth B, Wisnivesky JP.  2008.  Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.. Lung Cancer. 60(1):75-82.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.

Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Prive GG.  2008.  Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.. Mol Cell. 29(3):384-91.

Cerchietti LCA, Navigante AH, Castro MA.  2007.  Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.. Nutr Cancer. 59(1):14-20.

Cerchietti L.  2007.  Morphine mouthwashes for painful mucositis.. Support Care Cancer. 15(1):115-6;authorreply117.

Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.  2007.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.. Proc Natl Acad Sci U S A. 104(9):3207-12.

Cerchietti LCA, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar MEsther, Roth B, Negretti G, Sheinker B et al..  2006.  Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.. Int J Radiat Oncol Biol Phys. 65(5):1330-7.

Diament MJudith, Peluffo GDaniel, Stillitani I, Cerchietti LCarlos, Navigante A, Ranuncolo SMaris, Klein SMariana.  2006.  Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. Cancer Invest. 24(2):126-31.

Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FGuo, Augenlicht LH, Mariadason JM et al..  2006.  Kaiso-deficient mice show resistance to intestinal cancer.. Mol Cell Biol. 26(1):199-208.

Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME.  2006.  Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.. J Pain Symptom Manage. 31(1):38-47.

Cerchietti LCA, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BMC.  2005.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.. J Neurooncol. 71(1):73-81.

Cerchietti LCA, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME.  2004.  Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.. J Pain Symptom Manage. 27(1):85-95.